相关实验视频

Updated: Jan 11, 2026

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms

Published on: March 15, 2024

利用肠道衍生生物活性和人工智能诊断来为下一代2型糖尿病解决方案提供帮助

Yuliya Tseyslyer¹, Vladyslav Malyi², Mariia Saifullina¹

¹Educational and Scientific Centre, Institute of Biology and Medicine, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.

Frontiers in endocrinology

|November 19, 2025

概括

发现肠道微生物和人工智能 (AI) 如何彻底改变2型糖尿病 (T2D) 治疗. 这项研究探讨了针对个性化T2D管理和改善患者生活质量的新型治疗目标和AI诊断.

科学领域:

代谢性疾病研究研究.
微生物组科学微生物组科学
医学中的人工智能

背景情况:

2型糖尿病 (T2D) 影响全球超过5亿人,尽管目前的治疗方法,但患病率仍在上升.
传统的T2D疗法越来越无效,需要创新的预防,诊断和治疗策略.
肠道微生物群和人工智能 (AI) 为改变T2D管理提供了有希望的途径.

研究的目的:

分析对T2D肠道生物活性物质的全球经验.
评估AI在T2D管理中的诊断潜力.
为改善T2D治疗和生活质量开发一种全新的综合方法.

主要方法:

对微生物代谢物 (胆酸,短链脂肪酸) 和它们的治疗潜力的审查.
对临床诊断中人工智能应用的分析,重点关注微生物组数据和电子健康记录.
微生物组洞察力和人工智能能力的综合,提出新的治疗模式.

主要成果:

肠道微生物代谢物显示出对代谢障碍的治疗剂的潜力.
人工智能,特别是机器学习,可以提高T2D的诊断准确性和风险评估.
将微生物组数据与人工智能结合起来,可以实现个性化的监测和治疗策略.

结论:

结合肠道生物活性物质和人工智能诊断的新型模型可以导致适应性,个性化的T2D治疗.
这种方法旨在显著改善患者的生活质量和治疗结果.
对微生物组-人工智能协同作用的进一步研究对未来的代谢疾病管理充满希望.

关键词:

人工智能的人工智能是人工智能.闭环系统的闭环系统深度学习模型的深度学习模型数字双胞胎系统是一个数字双胞胎系统.我们的肠道微生物群.微生物组是一个微生物组.2 型糖尿病 2 型糖尿病

更多相关视频

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

相关概念视频

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Carbohydrate Metabolism

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...